Innomane

InnoMane is a South Korean biotechnology company specializing in the development of first-in-class therapeutics for hair loss and skin regeneration. The company's core technology focuses on modulating the Wnt/beta-catenin signaling pathway, a key regulator of hair follicle development and tissue repair. InnoMane's research identified CXXC-type zinc finger protein 5 (CXXC5) as a negative regulator of this pathway; their drug candidates are designed to disrupt the interaction between CXXC5 and the Dishevelled (Dvl) protein. By activating Wnt signaling, these therapies aim to promote hair growth and treat various dermatological conditions. The company's lead program, IM-101, is currently in Phase 1 clinical trials for the treatment of androgenetic alopecia.